1Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hoppitalized patients. J Am Soc Nephrol, 2005,16:3365 - 3370.
2Bagshaw SM, Uchino S, Bellomo R,et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol,2007 ,2 :431 -439.
3Molitoris BA, Levin A, Warnock DG, et al. Acute Kidney Injury Netowork: Improving outcomes form acute kidney injury. J Am Soc Nephrol, 2007, 18:1992 - 1994.
4Mehta RL, Pascual MT, Soroko S ,et al. Spectrum of acute renal failure in the intensive care unit:The PICARD experience. Kidney Int, 2004,66 : 1613 - 1621.
5Mariano F, Guida G, Donati D, et al. Production of platelet-activating factor in patients with sepsis-associated acute renal failure. Nephrol Dial Transplant, 1999, 14:1150-1157.
6Abernepthy VE, Lieberthal W. Acute renal failure in the critically ill patient. Crit Care Clin,2002,18:203 - 222.
7Haase-Fielitz A, Hasse M, Belloma R, et al. Genetic polymorphisms in sepsis-and cardiopulmonary bypass-associated acute kidney injury. In: Ronco C, Bellomo R, Kellum JA eds. Acute kidney injury. Contrib Nephrol. Basel: Karger, 2007, 156:75 - 91.
8Hotchikiss RS, Swanson PE, Freeman BD,et al. Apoptotic cell death in patients with sepsis, septic shock ,and multiple organ dysfunction. Crit Care Med, 1999,27 : 1230 - 1251.
9Diaz de Leon M, Moreno SA, Gonzales Dlaz DJ,et al. Severe sepsis as a cause of acute renal failure. Nefrologica,2006,26:439 -444.
10Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med, 2001, 344:699 -709.
二级参考文献14
1[1]Hirassawa H, Sugai T, Oda S, et al. Continous hemodiafiltration can remove humoral mediators from the blood stream of patients with SIRS/MODS. Abstr. Blood Purif,1997, 15:136
2[2]Heering P, Morgera S, Schmitz G, et al. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Med, 1997, 23:288
3[3]Kouche K,Cavadore P,Portales P, et al. Continous veno-venous hemofiltration improves hemodynamics in septic shock with acute renal failure without modifying TNF-α and IL-6 plasma concentrations. J Neprol, 2002, 15:150
4[4]Sander A,Armbruster W,Sander B, et al. Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but not alter IL-6 and TNF-α plasma concentrations. Intensive Care Med, 1997, 23:878
5[6]Sieberth HG,Kierdorf HP. Is cytokine removal by continuous hemofiltration feasible? Kidney Int. 1999, 56(Suppl. 72): S79
6[7]Silvester W. Mediator removal with CRRT: complement and cytokines. Am J Kidney Dis, 1997, 30 (Suppl.4): S38
7[8]Sibbald WJ, Vincent JL. Round table conference on clinical trial for the treatment of sepsis. Crit Care Med, 1995, 23:394
8[10]De vriese AS,Colardyn FA,Philipp JJ, et al. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol, 1999, 10: 846
9[11]Morgera S,Stowinski T,Melzer C, et al. Renal replacement therapy with high-cutoff hemofilters: Impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis, 2004, 43: 444
